Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 1

Alongi, Pierpaolo; Laudicella, Riccardo; Desideri, Isacco; Chiaravalloti, Agostino; Borghetti, Paolo; Quartuccio, Natale; Fiore, Michele; Evangelista, Laura; Marino, Lorenza; Caobelli, Federico; Tuscano, Carmelo; Mapelli, Paola; Lancellotta, Valentina; Annunziata, Salvatore; Ricci, Marcos Desídérío; Ciurlia, E.; Fiorentino, Alba

doi:10.1016/j.critrevonc.2019.01.011

Cited by 19 publications

(10 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has also been hypothesized that 18 Ffluorodeoxyglucose ( 18 F-FDG) may be a clinically useful surrogate hypoxia tracer [24]. If this hypothesis proves to be valid, 18 F-FDG PET/CT may turn out be a powerful imaging modality for LACC, since 18 F-FDG PET/CT already is used successfully to detect pathological lymph nodes and high-risk radiation therapy targets [25,26]. The potential of DCE-MRI as an imaging modality for providing hypoxia-associated biomarkers of the outcome of LACC was investigated in the study reported in this communication.…”

Section: Discussionmentioning

confidence: 99%

DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses

et al. 2020

View full text Add to dashboard Cite

Background: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) may provide biomarkers of the outcome of locally-advanced cervical carcinoma (LACC). There is, however, no agreement on how DCE-MR recordings should be analyzed. Previously, we have analyzed DCE-MRI data of LACC using non-model-based strategies. In the current study, we analyzed DCE-MRI data of LACC using the Tofts pharmacokinetic model, and the biomarkers derived from this analysis were compared with those derived from the non-model-based analyses. Methods: Eighty LACC patients given cisplatin-based chemoradiotherapy with curative intent were included in the study. Treatment outcome was recorded as disease-free survival (DFS) and overall survival (OS). DCE-MRI series were analyzed voxelwise to produce K trans and v e frequency distributions, and ROC analysis was used to identify the parameters of the frequency distributions having the greatest potential as biomarkers. The prognostic power of these parameters was compared with that of the non-model-based parameters LETV (low-enhancing tumor volume) and TVIS (tumor volume with increasing signal). Results: Poor DFS and OS were associated with low values of K trans , whereas there was no association between treatment outcome and v e . The K trans parameters having the greatest prognostic value were p35-K trans (the K trans value at the 35 percentile of a frequency distribution) and RV-K trans (the tumor subvolume with K trans values below 0.13 min − 1 ). Multivariate analysis including clinical parameters and p35-K trans or RV-K trans revealed that RV-K trans was the only independent prognostic factor of DFS and OS. There were significant correlations between RV-K trans and LETV and between RV-K trans and TVIS, and the prognostic power of RV-K trans was similar to that of LETV and TVIS. Conclusions: Biomarkers of the outcome of LACC can be provided by analyzing DCE-MRI series using the Tofts pharmacokinetic model. However, these biomarkers do not appear to have greater prognostic value than biomarkers determined by non-model-based analyses.

show abstract

Section: Discussionmentioning

confidence: 99%

DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses

et al. 2020

View full text Add to dashboard Cite

show abstract

“…First, the diagnostic imaging modalities performed before and after treatment were not standardized. The role of MRI and PET-CT is very important for head and neck tumors [19]. In the early phase of this study, treatment was sometimes started without evaluation by MRI (24/55) or PET-CT (42/55) because of the limited availability of these imaging modalities.…”

Section: Discussionmentioning

confidence: 99%

Invasion of pterygoid plates; an indicator for regional lymph node failure in maxillary sinus cancer

Kosugi

Kawamoto

Oshima

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: The aim of this study was to evaluate the long-term treatment results of combined superselective intraarterial chemotherapy and radiation therapy for advanced maxillary sinus cancer (MSC) and the incidence of regional lymph node failure, and to reveal the clinical and anatomical predictive factors for metastasis. Methods: We retrospectively evaluated 55 consecutive patients with locally advanced squamous cell carcinoma of the maxillary sinus who were treated with external radiotherapy and superselective intraarterial chemotherapy. Elective nodal irradiation (ENI) was performed only in the clinical node-positive (cN+) cases and not in the clinical node-negative (cN0) cases. Results: Thirty-eight patients were cN0, and 17 were cN+ at diagnosis. Regional lymph node metastases occurred in 7 of 38 patients with cN0, and 2 of 17 with cN+ during the median follow-up period of 36 months. There were more cases of high-grade (3 or 4) late adverse events in the ENI group than in the non-ENI group (13% vs. 41%, respectively; p = 0.03). In cN0 cases without ENI, invasion of the pterygoid plates (57% vs. 90%; p < 0.01) and oral cavity (35% vs. 92%; p = 0.02) was significantly correlated with a low 5-year regional recurrence-free rate. Conclusions: Patients with MCS and invasion of the pterygoid plates and oral cavity can be considered appropriate candidates for ENI.

show abstract

“…Clinical advanced stage: if groin or pelvic lymph nodes show metastatic involvement at ultrasound or if infiltration of cutaneous bridges, urethra, anus, or vagina are evident or suspicious, considering the higher risk for distant metastases, a whole-body assessment should be performed by conventional radiologic imaging (CT, plus or minus pelvic MRI) or metabolic imaging (by 18F FDG-PET/CT) (Salani et al 2017;Kataoka et al 2010;Robertson et al 2016;Viswanathan et al 2013;Collarino et al 2018Collarino et al , 2017Fiorentino et al 2019;Alongi et al 2019).…”

Section: Frailtymentioning

confidence: 99%

Personalizing vulvar cancer workflow in COVID-19 era: a proposal from Vul.Can MDT

Garganese

Tagliaferri

Fragomeni

et al. 2020

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

Introduction Since the community spread of Coronavirus disease 2019 (COVID-19), the practice of oncologic care at our comprehensive cancer center has changed. Postponing cancer treatment without consideration of its implications could cost more lives than can be saved. In this special situation, we must continue to provide our cancer patients with the highest quality of medical services assuring the safety. This article provides general guidance on supporting curative treatment strategies in vulvar cancer patients. Methods At our institution, a vulvar cancer multidisciplinary team (Vul.Can MDT) of specialists is responsible for personalized treatment of this disease. The phase 2 period necessarily requires specific procedures for both outpatient and inpatient pathways and to provide strategies concerning the management of vulvar cancer patients even in case of an eventually concomitant SARS-CoV-2 infection. In brief, an accurate remote and in person triage must be provided routinely and patients submitted to specific diagnostic tests prior to every major treatment or procedure (surgery, RT, and CT) or in case of suspicion for COVID-19 syndrome. The decisional workflow for these women often old and frail, have been rapidly adjusted by our Vul.Can MDT to mitigate the potential risks of COVID-19. Results The team produced two types of recommendations concerning: (1) safety regulations of care pathways, patients and health care providers, (2) personalized treatment strategies. We present a protocol that can be applied in clinical practice: the flowcharts provided, include the modulation of treatment intensity designed for surgical procedures and radiation, stratified for FIGO stage of disease and intention. Conclusion We suggest that our proposals are applicable in this setting of patients, considering anyway current international recommendations and guidelines.

show abstract

Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 1

Cited by 19 publications

References 66 publications

DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses

DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses

Invasion of pterygoid plates; an indicator for regional lymph node failure in maxillary sinus cancer

Personalizing vulvar cancer workflow in COVID-19 era: a proposal from Vul.Can MDT

Contact Info

Product

Resources

About